NIAID’s Comprehensive Support Mechanisms for Antibiotic Development

  15 June 2020

The National Institute of Allergy and Infectious Diseases (NIAID) recognizes the continuing threat of antimicrobial resistance and the need to develop new therapeutics and strategies to combat multidrug resistant organisms. NIAID leverages multiple mechanisms to help support antibiotic developers struggling in the “valley of death” of preclinical antibiotic development. The Division of Microbiology and Infectious Diseases’ (DMID) preclinical services are a comprehensive set of services to facilitate efforts to develop vaccines, diagnostics, and therapeutics for a broad array of bacterial, viral, fungal, and parasitic pathogens. These services are available to investigators worldwide at no charge.

Further reading: ACS Publications
Author(s): Erin M. Zeituni and Erica L. Raterman Cite
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!